Report cover image

Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

Publisher Renub Research
Published Jan 01, 2022
Length 130 Pages
SKU # RNBR16906336

Description

Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

Japan Proton Therapy Market Potential will be US$ 8.6 Billion by 2027. Over the years, various techniques for cancer treatment have emerged, such as chemotherapy, surgery, and proton therapy. The proton therapy is the new technology and is expected to least impair the quality of life compared to other forms of treatment. Japan has one of the highest numbers of proton therapy treatment clinics globally. The improving cutting-edge technology in radiotherapy and growing technological development in Japan will further drive the Japan proton therapy industry in the future.

COVID-19 Impact on Japan Proton Therapy Industry

Despite the outbreak of COVID-19 worldwide, the proton therapy market has grown at a constant rate. Proton therapy’s radiation therapy was stopped for a brief round period, but it was resumed for patients. In addition, to take care of the regular patient and radiation therapies patients in Japan, many processes have been finalized to help the patients with therapies; as such many implementations and algorithms have been carried out to safeguard the radiation patients from COVID-19.

Japan Proton Therapy Potential Market Size was US$ 6.1 Billion post-pandemic recoveries in 2021

The growth of the proton therapy market in Japan is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation, and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access and premium pricing. As these systems become more widespread, they are likely to require further refinement and enhancement to respond to the needs of medical staff.

Cancer Types - Market Segmentation

Based on Cancer Types, the proton therapy market of Japan is further segmented into Central Nervous System (CNS) Tumors, Head and Neck Cancer, Lung Cancer, GI (Gastro-Intestinal) Cancer, Hepatocellular Carcinoma (HCC) Cancer, Pancreas Cancer, Gynecologic Cancers, Prostate Cancer, Bone, and Soft Tissue Cancer and Other Cancer. According to Renub Research report, Japan Proton Therapy Industry is expected to grow with a CAGR of 5.9% during 2021-2027.

Besides, proton therapy applications are more inclined towards Gastrointestinal Tract Cancer and lung cancer due to references by healthcare specialists. Moreover, proton therapy is also recognized to be comparatively safer in the case of patients with central nervous system (CNS) tumors.

Although there is less experience with proton therapy combined with chemotherapy for pancreatic cancer, favorable outcomes have been reported recently in Japan. Remarkably, these applications are anticipated to drive the revenue for the proton therapy industry over the forecast period.

Competitive Landscape

Companies existing in the Japan Proton Therapy Market are trying to create their mark by adopting new technologies at an accelerated rate. The company has also tried to enrich its product catalogs through product developments. Also, companies have acquired small companies to resolve the potential resource gap that prevailed in their technologies and products. The major players of the Japan Proton Therapy Market studied in our report are IBA Proton Therapy, Varian Medical Systems, and Elekta.

Renub Research report ""Japan Proton Therapy Market, Patients by 10 Cancer Types (Central Nervous System (CNS), Head and Neck, Lung, GI (Gastro-Intestinal), Hepatocellular Carcinoma (HCC), Pancreas, Gynecologic, Prostate, Bone and Soft Tissue, Others), Companies (IBA Proton Therapy, Varian Medical Systems, Elekta)"" Reimbursement Policies & Persons Treated at Centers provides a comprehensive assessment of the fast-evolving, high-growth of Japan Proton Therapy Market.

Cancer Types – Japan Proton Therapy Number of Patients have been covered from 10 viewpoints:

1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer

Cancer Types – Japan Proton Therapy Market have been covered from 10 viewpoints:

1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer

All companies have been covered from 3 viewpoints:

• Overview
• Recent Developments
• Sales Analysis

Companies Covered:

1. IBA Proton Therapy
2. Varian Medical Systems
3. Elekta

Table of Contents

130 Pages
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Japan Proton Therapy Market (Actual & Untapped)
5.1 Actual Proton Therapy Market
5.2 Untapped Proton Therapy Market
6. Number of Patients – Japan Proton Therapy
6.1 Actual Numbers
6.2 Untapped Numbers
7. Cancer Types – Japan Proton Therapy Number of Patients
7.1 Central Nervous System (CNS) Tumors
7.2 Head and Neck Cancer
7.3 Lung Cancer
7.4 GI (Gastro-Intestinal) Cancer
7.5 Hepatocellular Carcinoma (HCC) Cancer
7.6 Pancreas Cancer
7.7 Gynecologic Cancers
7.8 Prostate Cancer
7.9 Bone and Soft Tissue Cancer
7.10 Others Cancer
8. Cancer Types – Japan Proton Therapy Market
8.1 Central Nervous System (CNS) Tumors
8.2 Head and Neck Cancer
8.3 Lung Cancer
8.4 GI (Gastro-Intestinal) Cancer
8.5 Hepatocellular Carcinoma (HCC) Cancer
8.6 Pancreas Cancer
8.7 Gynecologic Cancers
8.8 Prostate Cancer
8.9 Bone and Soft Tissue Cancer
8.10 Others Cancer
9. Japan – List of Proton Therapy Centers
9.1 Operating Proton Therapy Centers
9.2 Under-Construction Therapy Centers
10. Reimbursement Policies – Japan Proton Therapy
11. Components of a Standard Proton Therapy Center
11.1 Type of Proton Accelerator
11.1.1 Synchrotrons (example: LLUMC at Loma Linda)
11.1.2 Cyclotrons (example: MGH Boston)
11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
11.1.4 Linacs (Rome)
11.1.5 H-minus Synchrotrons
11.1.6 Separated Sector Cyclotrons
11.1.7 Super-conducting Cyclotrons
11.1.8 Fast Cycling Synchrotron
11.2 Beam Transport System
11.3 Beam Delivery System
11.3.1 The Passive Scattering Technique
11.3.2 Beam Scanning
11.4 Type of Nozzle
11.4.1 Single Scattering
11.4.2 Double Scattering
11.4.3 Uniform Scanning Nozzle
11.4.4 Pencil Scanning Nozzle
11.5 Treatment Planning System
11.6 Image Viewers
11.7 Patient Positioning System (PPS)
11.8 Human Resource
12. Porters Five Forces
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13. Company Analysis
13.1 IBA Proton Therapy
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Sales Analysis
13.2 Varian Medical Systems
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Sales Analysis
13.3 Elekta
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Sales Analysis
List Of Figures:
Figure-01: Japan – Actual Proton Therapy Market (Million US$), 2016 – 2021
Figure-02: Japan – Forecast for Actual Proton Therapy Market (Million US$), 2022 – 2027
Figure-03: Japan – Untapped Proton Therapy Market (Million US$), 2016 – 2021
Figure-04: Japan – Forecast for Untapped Proton Therapy Market (Million US$), 2022 – 2027
Figure-05: Japan – Actual Numbers (Number), 2016 – 2021
Figure-06: Japan – Forecast for Actual Numbers (Number), 2022 – 2027
Figure-07: Japan – Untapped Numbers (Number), 2016 – 2021
Figure-08: Japan – Forecast for Untapped Numbers (Number), 2022 – 2027
Figure-09: Japan – Central Nervous System (CNS) Tumors Patients (Number), 2016 – 2021
Figure-10: Japan – Forecast for Central Nervous System (CNS) Tumors Patients (Number), 2022 – 2027
Figure-11: Japan – Head and Neck Cancer Patients (Number), 2016 – 2021
Figure-12: Japan – Forecast for Head and Neck Cancer Patients (Number), 2022 – 2027
Figure-13: Japan – Lung Cancer Patients (Number), 2016 – 2021
Figure-14: Japan – Forecast for Lung Cancer Patients (Number), 2022 – 2027
Figure-15: Japan – GI (Gastro-Intestinal) Cancer Patients (Number), 2016 – 2021
Figure-16: Japan – Forecast for GI (Gastro-Intestinal) Cancer Patients (Number), 2022 – 2027
Figure-17: Japan – Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2016 – 2021
Figure-18: Japan – Forecast for Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2022 – 2027
Figure-19: Japan – Pancreas Cancer Patients (Number), 2016 – 2021
Figure-20: Japan – Forecast for Pancreas Cancer Patients (Number), 2022 – 2027
Figure-21: Japan – Gynecologic Cancers Patients (Number), 2016 – 2021
Figure-22: Japan – Forecast for Gynecologic Cancers Patients (Number), 2022 – 2027
Figure-23: Japan – Prostate Cancer Patients (Number), 2016 – 2021
Figure-24: Japan – Forecast for Prostate Cancer Patients (Number), 2022 – 2027
Figure-25: Japan – Bone and Soft Tissue Cancer Patients (Number), 2016 – 2021
Figure-26: Japan – Forecast for Bone and Soft Tissue Cancer Patients (Number), 2022 – 2027
Figure-27: Japan – Others Cancer Patients (Number), 2016 – 2021
Figure-28: Japan – Forecast for Others Cancer Patients (Number), 2022 – 2027
Figure-29: Japan – Central Nervous System (CNS) Tumors Market (Million US$), 2016 – 2021
Figure-30: Japan – Forecast for Central Nervous System (CNS) Tumors Market (Million US$), 2022 – 2027
Figure-31: Japan – Head and Neck Cancer Market (Million US$), 2016 – 2021
Figure-32: Japan – Forecast for Head and Neck Cancer Market (Million US$), 2022 – 2027
Figure-33: Japan – Lung Cancer Market (Million US$), 2016 – 2021
Figure-34: Japan – Forecast for Lung Cancer Market (Million US$), 2022 – 2027
Figure-35: Japan – GI (Gastro-Intestinal) Cancer Market (Million US$), 2016 – 2021
Figure-36: Japan – Forecast for GI (Gastro-Intestinal) Cancer Market (Million US$), 2022 – 2027
Figure-37: Japan – Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2016 – 2021
Figure-38: Japan – Forecast for Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2022 – 2027
Figure-39: Japan – Pancreas Cancer Market (Million US$), 2016 – 2021
Figure-40: Japan – Forecast for Pancreas Cancer Market (Million US$), 2022 – 2027
Figure-41: Japan – Gynecologic Cancers Market (Million US$), 2016 – 2021
Figure-42: Japan – Forecast for Gynecologic Cancers Market (Million US$), 2022 – 2027
Figure-43: Japan – Prostate Cancer Market (Million US$), 2016 – 2021
Figure-44: Japan – Forecast for Prostate Cancer Market (Million US$), 2022 – 2027
Figure-45: Japan – Bone and Soft Tissue Cancer Market (Million US$), 2016 – 2021
Figure-46: Japan – Forecast for Bone and Soft Tissue Cancer Market (Million US$), 2022 – 2027
Figure-47: Japan – Others Cancer Market (Million US$), 2016 – 2021
Figure-48: Japan – Forecast for Others Cancer Market (Million US$), 2022 – 2027
Figure-49: IBA Proton Therapy – Global Revenue (Million US$), 2016 – 2021
Figure-50: IBA Proton Therapy – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-51: Varian Medical Systems – Global Revenue (Million US$), 2016 – 2021
Figure-52: Varian Medical Systems – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-53: Elekta – Global Revenue (Million US$), 2016 – 2021
Figure-54: Elekta – Forecast for Global Revenue (Million US$), 2022 – 2027
List Of Tables:
Table-1: Japan – Proton Therapy Centers in Operation
Table-2: Japan – Proton Therapy Centers in Under-Construction

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us